Daniel Rea

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Suzanne F. Jones, Ian Judson, D. Rea, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

John M S Bartlett, Hein Putter, Cornelis J H van de Velde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.